Organization
North Estonia Medical Centre Foundation
3 abstracts
Abstract
Clinical validation of a prognostic 7-marker IHC assay (7-IHC) in 382 patients (pts) with stage IB/IIA cutaneous melanoma (CM; MELARISK-001).Org: University Medical Center Gronigen, Groningen University, Dr Balmis General University Hospital, Institute for Health and Biomedical Research (ISABIAL), North Estonia Medical Centre Foundation,
Abstract
Integration of trastuzumab (T), with or without pertuzumab (P), into perioperative chemotherapy (CT) of HER-2 positive gastric (GC) and esophagogastric junction cancer (EGJC): First results of the EORTC 1203 INNOVATION study, in collaboration with the Korean Cancer Study Group, and the Dutch Upper GI Cancer group.Org: Grow School for Oncology and Reproduction, European Organisation for Research and Treatment of Cancer (EORTC) Headquarters, European Institute of Oncology - IRCCS, Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea, Robert Debré University Hospital,
Abstract
Pembrolizumab vs placebo for early-stage non‒small-cell lung cancer after resection and adjuvant therapy: Subgroup analysis of patients who received adjuvant chemotherapy in the phase 3 PEARLS/KEYNOTE-091 study.Org: North Estonia Medical Centre Foundation, The Catholic University of Korea, Hiroshima University Hospital, Wielkopolskie Centrum Pulmonologii i Torakochirurgii im. Eugenii i Janusza Zeylandów, Medical Oncology 2, Istituto Oncologico Veneto IOV IRCCS, Padova, Italy,